Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Fruh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi99–105. doi: 10.1093/annonc/mdt178
   PubMed Web of Science ®Google Scholar
• Wen S, Dai L, Wang L, et al. Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncology. 2019;24(11):e1070–e1081. doi: 10.1634/theoncologist.2018-0572
   Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a New Pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi: 10.1158/1078-0432.CCR-16-1741
   PubMed Web of Science ®Google Scholar
• Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015;33(18):2004–2012. doi: 10.1200/JCO.2014.58.3708
   PubMed Web of Science ®Google Scholar
• Guo H, Li W, Wang B, et al. Coexisting opportunities and challenges: in which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer? Chin J Cancer Res. 2021;33(5):574–582. doi: 10.21147/j.issn.1000-9604.2021.05.04
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi: 10.6004/jnccn.2021.0012
   PubMed Web of Science ®Google Scholar
• Pantel K, Alix-Panabieres C. Tumour microenvironment: informing on minimal residual disease in solid tumours. Nat Rev Clin Oncol. 2017;14(6):325–326. doi: 10.1038/nrclinonc.2017.53
   PubMed Web of Science ®Google Scholar
• Beiter T, Fragasso A, Hudemann J, et al. Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clin Chem. 2011;57(4):633–636. doi: 10.1373/clinchem.2010.158030
   PubMed Web of Science ®Google Scholar
• Snyder MW, Kircher M, Hill AJ, et al. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell. 2016;164(1–2):57–68. doi: 10.1016/j.cell.2015.11.050
   PubMed Web of Science ®Google Scholar
• Cheng ML, Pectasides E, Hanna GJ, et al. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. Ca A Cancer J Clinicians. 2021;71(2):176–190. doi: 10.3322/caac.21650
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Uddin MH, Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi: 10.1186/s12943-021-01371-1
   PubMed Web of Science ®Google Scholar
• Diaz LA Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586. doi: 10.1200/JCO.2012.45.2011
   PubMed Web of Science ®Google Scholar
• Hosseini H, Obradovic MMS, Hoffmann M, et al. Early dissemination seeds metastasis in breast cancer. Nature. 2016;540(7634):552–558. doi: 10.1038/nature20785
   PubMed Web of Science ®Google Scholar
• Badia-Ramentol J, Linares J, Gomez-Llonin A, et al. Minimal residual disease, metastasis and immunity. Biomolecules. 2021;11(2):130. doi: 10.3390/biom11020130
   PubMed Web of Science ®Google Scholar
• Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274–284. doi: 10.1038/nrc2622
   PubMed Web of Science ®Google Scholar
• Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–622. doi: 10.1038/nrc3793
   PubMed Web of Science ®Google Scholar
• Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol. 2012;2(5):120066. doi: 10.1098/rsob.120066
   PubMedGoogle Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nature Med. 2011;17(3):313–319. doi: 10.1038/nm.2304
   PubMed Web of Science ®Google Scholar
• Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev. 2011;21(1):42–49. doi: 10.1016/j.gde.2010.10.011
   PubMed Web of Science ®Google Scholar
• Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer. 2010;10(12):871–877. doi: 10.1038/nrc2933
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834–846. doi: 10.1038/nrc2256
   PubMed Web of Science ®Google Scholar
• Papadaki MA, Stoupis G, Theodoropoulos PA, et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Mol Cancer Ther. 2019;18(2):437–447. doi: 10.1158/1535-7163.MCT-18-0584
   PubMed Web of Science ®Google Scholar
• Ortiz-Otero N, Marshall JR, Lash B, et al. Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients. BMC Cancer. 2020;20(1):873. doi: 10.1186/s12885-020-07376-1
   PubMed Web of Science ®Google Scholar
• Blatter S, Rottenberg S. Minimal residual disease in cancer therapy–small things make all the difference. Drug Resist Updat. 2015;21-22:1–10. doi: 10.1016/j.drup.2015.08.003
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577–586. doi: 10.1038/s41571-018-0058-3
   PubMed Web of Science ®Google Scholar
• Frisone D, Friedlaender A, Addeo A. The role and impact of minimal residual disease in NSCLC. Curr Oncol Rep. 2021;23(12):136. doi: 10.1007/s11912-021-01131-w
   PubMed Web of Science ®Google Scholar
• Chudacek J, Bohanes T, Klein J, et al. Detection of minimal residual disease in lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech. 2014;158(2):189–193. doi: 10.5507/bp.2013.019
   PubMed Web of Science ®Google Scholar
• Racila E, Euhus D, Weiss AJ, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95(8):4589–4594. doi: 10.1073/pnas.95.8.4589
   PubMed Web of Science ®Google Scholar
• Coakley M, Garcia-Murillas I, Turner NC. Molecular residual disease and adjuvant trial design in solid tumors. Clin Cancer Res. 2019;25(20):6026–6034. doi: 10.1158/1078-0432.CCR-19-0152
   PubMed Web of Science ®Google Scholar
• Mathe G, Weiner R, Pouillart P, et al. BCG in cancer immunotherapy: experimental and clinical trials of its use in treatment of leukemia minimal and or residual disease. Natl Cancer Inst Monogr. 1973;39:165–175.
   PubMedGoogle Scholar
• Matthews MJ, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. Cancer Chemother Rep Part. 1973;3(2):63–67.
   Google Scholar
• Chen ZL. An immunohistochemical study of occult micrometastases in regional lymph nodes of patients with stage I non-small cell lung carcinoma. Zhonghua Zhong Liu Za Zhi. 1992;14(6):423–426.
   PubMedGoogle Scholar
• Marchetti A, Buttitta F, Carnicelli V, et al. Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. Diagn Mol Pathol: Am J Surg Pathol Part B. 1997;6(4):185–191. doi: 10.1097/00019606-199708000-00002
   PubMedGoogle Scholar
• Anker P, Stroun M. Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia. 2001;15(2):289–291. doi: 10.1038/sj.leu.2402016
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nature Med. 2014;20(5):548–554. doi: 10.1038/nm.3519
   PubMed Web of Science ®Google Scholar
• Kazemifard N, Sadeghi A, Varaminian B, et al. Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients. Gastroenterol Hepatol Bed Bench. 2019;12(Suppl1):S14–S21.
   Google Scholar
• Amatu A, Schirripa M, Tosi F, et al. High circulating methylated DNA is a negative predictive and prognostic marker in metastatic colorectal cancer patients treated with Regorafenib. Front Oncol. 2019;9:622. doi: 10.3389/fonc.2019.00622
   PubMed Web of Science ®Google Scholar
• Chen K, Zhang J, Guan T, et al. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017;154(3):1123–31e2. doi: 10.1016/j.jtcvs.2017.04.073
   PubMed Web of Science ®Google Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discovery. 2017;7(12):1394–1403. doi: 10.1158/2159-8290.CD-17-0716
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci, Trans Med. 2015;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021
   PubMed Web of Science ®Google Scholar
• Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci, Trans Med. 2016;8(346):346ra92. doi: 10.1126/scitranslmed.aaf6219
   PubMed Web of Science ®Google Scholar
• Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. 2021;595(7867):432–437. doi: 10.1038/s41586-021-03642-9
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi: 10.1038/nature22364
   PubMed Web of Science ®Google Scholar
• Fang X, Yu S, Jiang Y, et al. Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer. Front Oncol. 2022;12:1027664. doi: 10.3389/fonc.2022.1027664
   PubMed Web of Science ®Google Scholar
• Vendrell JA, Mazieres J, Senal R, et al. Ultra-sensitive EGFR (T790M) detection as an independent prognostic marker for lung cancer patients harboring EGFR (del19) mutations and treated with first-generation TKIs. Clin Cancer Res. 2019;25(14):4280–4289. doi: 10.1158/1078-0432.CCR-18-2683
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162. doi: 10.1182/blood-2008-11-185132
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Xie H, Urrutia R, et al. The promise of Circulating Tumor DNA (ctDNA) in the management of early-stage colon cancer: a critical review. Cancers. 2020;12(10):2808. doi: 10.3390/cancers12102808
   PubMed Web of Science ®Google Scholar
• Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol. 2020;17(12):757–770. doi: 10.1038/s41571-020-0392-0
   PubMed Web of Science ®Google Scholar
• Cescon DW, Bratman SV, Chan SM, et al. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1(3):276–290. doi: 10.1038/s43018-020-0043-5
   PubMedGoogle Scholar
• Shields MD, Chen K, Dutcher G, et al. Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer. Int J Mol Sci. 2022;23(16):9006. doi: 10.3390/ijms23169006
   PubMed Web of Science ®Google Scholar
• Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35(1):36. doi: 10.1186/s40880-016-0092-4
   PubMedGoogle Scholar
• Little S. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. 2001; Chapter 9:Unit 9 8. Chapter 9. doi: 10.1002/0471142905.hg0908s07
   PubMedGoogle Scholar
• Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013;10(10):1003–1005. doi: 10.1038/nmeth.2633
   PubMed Web of Science ®Google Scholar
• Garrido P, Paz-Ares L, Majem M, et al. LungBEAM: a prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Med. 2021;10(17):5878–5888. doi: 10.1002/cam4.4135
   PubMed Web of Science ®Google Scholar
• Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci, trans med. 2012;4(136):136ra68. doi: 10.1126/scitranslmed.3003726
   PubMed Web of Science ®Google Scholar
• Kinde I, Wu J, Papadopoulos N, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci USA. 2011;108(23):9530–9535. doi: 10.1073/pnas.1105422108
   PubMed Web of Science ®Google Scholar
• Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555. doi: 10.1038/nbt.3520
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Soo J, Co Ting Keh L, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537–1547. doi: 10.1038/s41587-021-00981-w
   PubMed Web of Science ®Google Scholar
• Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Med. 2017;23(6):703–713. doi: 10.1038/nm.4333
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245–251. doi: 10.1038/s41586-020-2140-0
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci, trans med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.3007094
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(5):497–530. doi: 10.6004/jnccn.2022.0025
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51. doi: 10.1016/j.jtho.2015.09.009
   PubMed Web of Science ®Google Scholar
• Peng M, Huang Q, Yin W, et al. Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer. Front Oncol. 2020;10:561598.
   PubMed Web of Science ®Google Scholar
• Kuang PP, Li N, Liu Z, et al. Circulating tumor DNA analyses as a potential marker of recurrence and effectiveness of adjuvant chemotherapy for resected non-small-cell lung cancer. Front Oncol. 2020;10:595650.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhao H, Shi Y, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res. 2019;25(23):7058–7067. doi: 10.1158/1078-0432.CCR-19-1213
   PubMed Web of Science ®Google Scholar
• Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12(1):6770. doi: 10.1038/s41467-021-27022-z
   PubMed Web of Science ®Google Scholar
• Zviran A, Schulman RC, Shah M, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nature Med. 2020;26(7):1114–1124. doi: 10.1038/s41591-020-0915-3
   PubMed Web of Science ®Google Scholar
• Ohara S, Suda K, Sakai K, et al. Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot study. Transl Lung Cancer Res. 2020;9(5):1915–1923. doi: 10.21037/tlcr-20-505
   PubMed Web of Science ®Google Scholar
• Zhang JT, Liu SY, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discovery. 2022;12(7):1690–1701. doi: 10.1158/2159-8290.CD-21-1486
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. doi: 10.1200/JCO.1995.13.1.8
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, et al. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565. doi: 10.1200/JCO.19.00201
   PubMed Web of Science ®Google Scholar
• Tang C, Lee WC, Reuben A, et al. Immune and circulating tumor DNA profiling after radiation treatment for oligometastatic non-small cell lung cancer: translational correlatives from a mature randomized phase II trial. Int J Radiat Oncol Biol Phys. 2020;106(2):349–357. doi: 10.1016/j.ijrobp.2019.10.038
   PubMed Web of Science ®Google Scholar
• Ma L, Xiang J. Clinical outcomes of video-assisted thoracic surgery and stereotactic body radiation therapy for early-stage non-small cell lung cancer: a meta-analysis. Thorac Cancer. 2016;7(4):442–451. doi: 10.1111/1759-7714.12352
   PubMed Web of Science ®Google Scholar
• Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101(2):250–425. doi: 10.1016/j.radonc.2011.09.017
   PubMed Web of Science ®Google Scholar
• Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176–183. doi: 10.1038/s43018-019-0011-0
   PubMedGoogle Scholar
• Xia S, Ye J, Chen Y, et al. Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. Transl Lung Cancer Res. 2019;8(6):1016–1028. doi: 10.21037/tlcr.2019.12.09
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Nabet BY, Rizvi H, et al. Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clin Cancer Res. 2020;26(12):2849–2858. doi: 10.1158/1078-0432.CCR-19-3418
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Narayan A, Kole AJ, et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res. 2018;24(8):1872–1880. doi: 10.1158/1078-0432.CCR-17-1341
   PubMed Web of Science ®Google Scholar
• Jia Q, Chiu L, Wu S, et al. Tracking neoantigens by personalized circulating tumor DNA sequencing during checkpoint blockade immunotherapy in non-small cell lung cancer. Adv Sci. 2020;7(9):1903410. doi: 10.1002/advs.201903410
   Web of Science ®Google Scholar
• Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26(21):3552–3559. doi: 10.1200/JCO.2007.13.9030
   PubMed Web of Science ®Google Scholar
• Xia L, Mei J, Kang R, et al. Perioperative ctDNA-Based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res. 2022;28(15):3308–3317. doi: 10.1158/1078-0432.CCR-21-3044
   PubMed Web of Science ®Google Scholar
• Chae YK, Oh MS. Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions. J Thorac Oncol. 2019;14(1):16–24. doi: 10.1016/j.jtho.2018.09.022
   PubMed Web of Science ®Google Scholar
• Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415–1426. doi: 10.1016/S0140-6736(16)00004-0
   PubMed Web of Science ®Google Scholar
• Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-Mutated non-small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi: 10.1056/NEJMoa2027071
   PubMed Web of Science ®Google Scholar
• Mok T, Wu YL, Lee JS, et al. Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res. 2015;21(14):3196–3203. doi: 10.1158/1078-0432.CCR-14-2594
   PubMed Web of Science ®Google Scholar
• Herbst RS, Giaccone G, Marinis F, et al. Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med. 2020;383(14):1328–1339. doi: 10.1056/NEJMoa1917346
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31(6):798–806. doi: 10.1016/j.annonc.2020.03.287
   PubMed Web of Science ®Google Scholar
• Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580–6587. doi: 10.1158/1078-0432.CCR-12-1362
   PubMed Web of Science ®Google Scholar
• Guo N, Lou F, Ma Y, et al. Circulating tumor DNA detection in lung cancer patients before and after surgery. Sci Rep. 2016;6(1):33519. doi: 10.1038/srep33519
   PubMedGoogle Scholar
• Waldeck S, Mitschke J, Wiesemann S, et al. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. Mol Oncol. 2022;16(2):527–537. doi: 10.1002/1878-0261.13116
   PubMed Web of Science ®Google Scholar
• Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative Intent. J Clin Oncol. 2022;40(6):567–575. doi: 10.1200/JCO.21.01929
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19–20. doi: 10.1038/ng1054
   PubMed Web of Science ®Google Scholar
• Assaf ZJF, Zou W, Fine AD, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023;29(4):859–868. doi: 10.1038/s41591-023-02226-6
   PubMedGoogle Scholar